TABLE 3.

Univariate and multivariable analyses for variables associated with OS in the obesity group (n = 49).

Characteristics	Category	Univariate analysis HR (95%CI)	p	Multivariate analysis HR (95%CI)	p
Treatment	Anlotinib vs. placebo	1.792 (0.758–4.233)	0.184	2.326 (0.766–7.057)	0.136
Age	>60 vs. ≤60	0.634 (0.317–1.268)	0.198	0.463 (0.181–1.184)	0.108
Gender	Male vs. female	0.878 (0.460–1.676)	0.694	0.462 (0.130–1.647)	0.234
Smoking history	Current/former vs. never	1.149 (0.586–2.254)	0.686	2.843 (0.827–9.771)	0.097
ECOG	1–2 vs. 0	0.975 (0.492–1.930)	0.942	1.057 (0.462–2.419)	0.896
Histology	Squamous vs. adenocarcinoma	2.227 (0.911–5.449)	0.079	2.580 (0.688–9.677)	0.160
EGFR mutation	Positive vs. negative	1.095 (0.501–2.397)	0.820	1.551 (0.555–4.336)	0.402
Number of metastases	>3 vs. ≤3	1.575 (0.823–3.013)	0.170	2.542 (1.079–5.987)	0.033
Lines of previous chemotherapy	≥3 vs. 1–2	0.857 (0.441–1.665)	0.649	0.879 (0.374–2.064)	0.767
Previous Targeted treatment	Yes vs. no	1.069 (0.556–2.057)	0.841	0.536 (0.179–1.601)	0.264
Radiotherapy history	Yes vs. no	1.652 (0.863–3.163)	0.130	2.046 (0.821–5.096)	0.124

The bold values mean that the p value was considered statistically significant.

Abbreviations: Overall survival (OS); hazard ratio (HR); Eastern Cooperative Oncology Group (ECOG); epidermal growth factor receptor (EGFR).